Fritextsökning
Artiklar per år
Innehållstyper
-
Tuberkulosbakterier ska svältas ut - ny substans prövas på människa
Det amerikanska forskningsföretaget Calibr planerar att under ett år genomföra en klinisk studie med ett nytt sorts läkemedels mot tuberkulos.
-
Healthcap: ”Rätt mycket torrt krut kvar”
Riskkapitalbolaget Healthcap, med inriktning mot life science, investerar för närvarande i bolagets åttonde fond. Hittills har investeringar skett i 13 olika bolag i fonden.
-
Företag i Kanada får börja tillverka kokain
Ett företag i den kanadensiska provinsen British Columbia har fått tillstånd att tillverka och sälja kokain på licens.
-
“An entire industry is about to be wiped out”
According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden speaks to believe that the results must be taken seriously, and call for action from the Swedish authorities.
-
Column: ”Life as a F1 race”
"The F1 car makes several pit stops during a race and during a lifetime the human being may also have to come in several times for maintenance", Björn Ursing writes in a column.
-
New issue of Life Science Sweden!
The international issue of Life Science Sweden has been sent to press.
-
Editorial: ”AI that both impresses and frightens”
”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writes in an editorial.
-
Hello Jenni Nordborg!
Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.
-
A surprising discovery about the immune system in cases of cancer
Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising discovery about the function of the immune system.
-
Lundaforskare vill testa Crispr för diabetesgen
En gen som visat sig ha en koppling till försämrad insulinfrisättning i en ny studie hoppas forskarna kan vara en möjlig måltavla för framtida behandlingar mot typ 2-diabetes.
-
Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”
”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigård writes in a column.
-
Individual DNA passport could result in fewer drug side effects
You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer side effects if the drug treatment is adapted to their genes.
-
Uppsalaföretag beviljas särläkemedelsstatus i USA
Uppsalaföretaget Beactica Therapeutics har nu beviljats särläkemedelsstatus i USA för sitt läkemedel BEA-17 för behandling av glioblastom.
-
The government proposes fines for pharmaceutical companies that fail to notify drug shortages in time
According to a compilation from the Swedish Medicines Agency, the number of residually notified medicines increased by 54 % in Sweden last year compared to the previous year. In a bill presented by the government a number of proposals are put forward to counteract the problem.
-
He saved lives with his theories – was ostracised and ended up in a mental hospital
Hungarian doctor Ignaz Semmelweis (1818-1865) undoubtedly possessed plenty of persistence, diligence and sound reasoning skills – but he was hardly blessed with luck and timing.
-
Nanexa ingår avtal med Novo Nordisk om 46 miljoner
-
”Alla skriker efter talang”
Att locka till sig begåvningarna är en av life science-branschens stora framtidsutmaningar. Det var en av slutsatserna i det panelsamtal som avslutade konferensen New Horizons in Biologics & Bioprocessing på torsdagen.
-
SDS Life Science växer – tillsätter ny regionchef
SDS Life Science expanderar i Uppsala. Nu skapar koncernen en ny tjänst – där Christina Erixon kliver in som regionchef.
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and with the help of, among other things, a Swedish-developed invention, communication with the outside world can continue. “It’s their window to the world,” says ALS researcher Caroline Ingre.
-
Medivir i möte med FDA: "Positiv återkoppling"
Forskningsbolaget Medivir har genomfört ett så kallat pre-IND-möte med den amerikanska läkemedelsmyndigheten FDA.
-
Great Swedish innovations: Eye treatment became a feather in Pharmacia’s cap
From complicated and sometimes risky surgery to a routine procedure. Pharmacia’s injectable Healon revolutionised the field of eye surgery - and is considered by us one of the most important contemporary Swedish innovations in the field of medicine.
-
Ny ordförande för Atlas Antibodies
Åsa Riisberg, styrelseproffs och tidigare partner i EQT, tar över ordförandeklubban i Atlas Antibodies.
-
She creates pharmaceuticals on a 3D printer
The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a well-advanced project with 3D-printed drugs at Uppsala University. “It will soon be available